Nyxoah S.A. (NYXH)
USD 6.12
(1.75%)
USD 6.12
(1.75%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 26.04 Million EUR | 1.16% |
| 2022 | 25.74 Million EUR | 15.94% |
| 2021 | 22.2 Million EUR | 31.49% |
| 2020 | 16.89 Million EUR | 47.1% |
| 2019 | 11.48 Million EUR | 52.58% |
| 2018 | 7.52 Million EUR | 13.71% |
| 2017 | 6.61 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 25.64 Million EUR | -1.55% |
| 2024 Q2 | 28.02 Million EUR | 9.54% |
| 2023 Q1 | 25.92 Million EUR | 0.7% |
| 2023 Q3 | 26.05 Million EUR | -2.9% |
| 2023 Q4 | 26.04 Million EUR | -0.05% |
| 2023 Q2 | 26.83 Million EUR | 3.51% |
| 2023 FY | 26.04 Million EUR | 1.16% |
| 2022 Q1 | 23.36 Million EUR | 5.19% |
| 2022 FY | 25.74 Million EUR | 15.94% |
| 2022 Q4 | 25.74 Million EUR | -16.95% |
| 2022 Q3 | 31 Million EUR | 8.25% |
| 2022 Q2 | 28.63 Million EUR | 22.59% |
| 2021 Q4 | 22.2 Million EUR | 0.0% |
| 2021 FY | 22.2 Million EUR | 31.49% |
| 2021 Q2 | 23.27 Million EUR | 21.55% |
| 2021 Q1 | 19.14 Million EUR | 13.36% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q4 | 16.89 Million EUR | 0.0% |
| 2020 Q3 | 16.89 Million EUR | 32.41% |
| 2020 Q2 | 12.75 Million EUR | 0.0% |
| 2020 FY | 16.89 Million EUR | 47.1% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 Q4 | 11.48 Million EUR | -10.53% |
| 2019 Q3 | 12.83 Million EUR | 0.0% |
| 2019 FY | 11.48 Million EUR | 52.58% |
| 2018 FY | 7.52 Million EUR | 13.71% |
| 2017 FY | 6.61 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 126.59 Million USD | 79.427% |
| AngioDynamics, Inc. | 112.08 Million USD | 76.763% |
| AtriCure, Inc. | 147.76 Million USD | 82.374% |
| Avinger, Inc. | 19.97 Million USD | -30.408% |
| Azenta, Inc. | 351.22 Million USD | 92.584% |
| BioLife Solutions, Inc. | 75.05 Million USD | 65.297% |
| The Cooper Companies, Inc. | 4.1 Billion USD | 99.366% |
| Daxor Corporation | 858.75 Thousand USD | -2932.868% |
| Ekso Bionics Holdings, Inc. | 16.31 Million USD | -59.668% |
| Femasys Inc. | 9.4 Million USD | -176.979% |
| GlucoTrack, Inc. | 1.7 Million USD | -1424.883% |
| Harvard Bioscience, Inc. | 64.29 Million USD | 59.49% |
| Hologic, Inc. | 4.02 Billion USD | 99.353% |
| ICU Medical, Inc. | 2.25 Billion USD | 98.845% |
| Intuitive Surgical, Inc. | 2.04 Billion USD | 98.726% |
| KORU Medical Systems, Inc. | 8.1 Million USD | -221.258% |
| LeMaitre Vascular, Inc. | 48.87 Million USD | 46.714% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -3846.595% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -3846.595% |
| Masimo Corporation | 1.67 Billion USD | 98.447% |
| Microbot Medical Inc. | 3.82 Million USD | -580.737% |
| Meihua International Medical Technologies Co., Ltd. | 25.07 Million USD | -3.858% |
| Merit Medical Systems, Inc. | 1.12 Billion USD | 97.681% |
| Nephros, Inc. | 3.5 Million USD | -643.506% |
| NovoCure Limited | 783.63 Million USD | 96.676% |
| NEXGEL, Inc. | 4.78 Million USD | -443.85% |
| NEXGEL, Inc. | 4.78 Million USD | -443.85% |
| Singular Genomics Systems, Inc. | 86.46 Million USD | 69.877% |
| OraSure Technologies, Inc. | 52.17 Million USD | 50.08% |
| Pro-Dex, Inc. | 23.34 Million USD | -11.575% |
| Pulse Biosciences, Inc. | 16.44 Million USD | -58.386% |
| Predictive Oncology Inc. | 6.14 Million USD | -323.808% |
| Precision Optics Corporation, Inc. | 6.84 Million USD | -280.509% |
| QuidelOrtho Corporation | 3.55 Billion USD | 99.268% |
| Repligen Corporation | 853.2 Million USD | 96.947% |
| Sanara MedTech Inc. | 29.28 Million USD | 11.058% |
| STAAR Surgical Company | 102.73 Million USD | 74.649% |
| Sharps Technology, Inc. | 3.85 Million USD | -575.619% |
| Utah Medical Products, Inc. | 7.14 Million USD | -264.521% |
| DENTSPLY SIRONA Inc. | 4.07 Billion USD | 99.361% |
| Jin Medical International Ltd. | 8.92 Million USD | -191.842% |